Loading
Chemotherapy and radiation, then surgery, then a year of immunotherapy if the operation shows cancer was still there. This is the current curative-intent pathway.
CROSS gives 10-year OS of 38%; CheckMate 577 adds DFS 22.4 vs 11.0 months in the ~70% with residual disease after resection (OS HR 0.85, not significant). Patients with pathologic complete response do not receive nivolumab. SANO offers surveillance instead of surgery for clinical complete responders.
Shares SANO, CROSS, Paclitaxel / nab-paclitaxel, Oesophageal cancer.
Shares SANO, Clinical complete response (cCR), CROSS, Oesophageal cancer.
Shares CheckMate 577, Nivolumab.
Shares CheckMate 577, Oesophageal cancer, Nivolumab.
Shares SANO, CROSS, Oesophageal cancer.
Shares Clinical complete response (cCR), Neoadjuvant / adjuvant / perioperative, Nivolumab.
Shares CROSS, Oesophageal cancer.
Shares Neoadjuvant / adjuvant / perioperative, Paclitaxel / nab-paclitaxel, Nivolumab, Carboplatin.